CORONA Remedies Limited has reported its unaudited financial results for the quarter and half-year ended September 30, 2026. The company posted a robust 22.2% year-on-year growth in revenue from operations for Q2 FY27, reaching ₹441.2 crore. Profit After Tax also saw a significant increase of 15.3% to ₹60.3 crore for the quarter. Consolidated results also demonstrate strong performance, with revenue up 22.0% to ₹863.6 crore in H1 FY27.
CORONA Remedies Reports Strong Q2 FY27 Financials
CORONA Remedies Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026, showcasing significant growth across key financial metrics. The company achieved its highest ever revenue, with a 22.2% year-on-year increase in Q2 FY27 revenue from operations, amounting to ₹441.2 crore. This growth rate was 1.9 times the industry’s IPM growth.
Standalone Financial Highlights
For the quarter ended September 30, 2026, standalone revenue from operations stood at ₹441.2 crore, compared to ₹361.1 crore in the corresponding period of the previous year. EBITDA for the quarter was ₹96.0 crore, a 22.3% increase. Profit After Tax (PAT) for the quarter was ₹60.3 crore, up 15.3% from ₹52.3 crore in Q2 FY26. PAT margin stood at 13.7%.
Consolidated Performance
On a consolidated basis, CORONA Remedies reported revenue of ₹863.6 crore for the half-year ended September 30, 2026, marking a 22.0% increase from ₹707.7 crore in H1 FY26. EBITDA grew by 27.5% to ₹189.1 crore. The consolidated Profit After Tax for the half-year was ₹120.4 crore, a substantial 22.2% rise from ₹98.5 crore in the prior year period. The company highlighted that PAT and PAT Margins were impacted by higher depreciation and amortization charges due to newly commissioned facilities and brand acquisitions.
Key Business Developments
The company emphasized its outperformance in the IPM market, with revenue growth significantly exceeding the industry average. CORONA Remedies now boasts 4 brands exceeding ₹100 crore in annual sales, with one brand crossing ₹200 crore. Operational excellence was noted, with volume growth, pricing, and new introductions all outperforming the IPM.
Furthermore, the company’s chronic and semi-chronic business segment experienced substantial growth, contributing 71.2% of the total. The ANVISA GMP certification for its Bhayla manufacturing facility in Brazil, covering Oral Solid Dosage and Women’s Hormone production, was highlighted as a key milestone strengthening its manufacturing capabilities.
Investor Contact Information
For further information, investors can contact CORONA Remedies Limited via Investor Relations Advisors, Strategic Growth Advisors Pvt Ltd. at [email protected] or [email protected].
Source: BSE
